Obstruction of pelviureteric junction
|
0.700 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
Obstruction of pelviureteric junction
|
0.700 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
Obstruction of pelviureteric junction
|
0.700 |
Biomarker
|
phenotype |
HPO |
|
|
|
MULTICYSTIC RENAL DYSPLASIA, BILATERAL
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|
MULTICYSTIC RENAL DYSPLASIA, BILATERAL
|
0.400 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Hydronephrosis Due To Pujo
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Flank Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hydronephrosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Nephrotic Syndrome
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Renal Cell Dysplasia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital hypoplasia of kidney
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital dilatation of ureter
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Sarcoma of kidney
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dilatation of ureter
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Cystic renal dysplasia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Renal dysplasia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Multicystic Dysplastic Kidney
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Three intragenic Tbx18 polymorphisms were used to map the region of maximum AI to within the gene itself; 16 of 17 tumours exhibited imbalances of at least one of these markers.
|
12663494 |
2003 |
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry validated the discriminative value of corresponding endothelial protein expression between early (fractalkine/CX3CL1, IP10/CCL10, TBX18) or advanced (BAX, NFKB2) stages of atherosclerosis and versus their plaque-free controls.
|
17591977 |
2007 |
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry validated the discriminative value of corresponding endothelial protein expression between early (fractalkine/CX3CL1, IP10/CCL10, TBX18) or advanced (BAX, NFKB2) stages of atherosclerosis and versus their plaque-free controls.
|
17591977 |
2007 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Analysis of tumor suppressor properties of two aberrantly methylated transcription factors, HOXB13 and TBX18, revealed that both inhibited growth and clonogenic survival of colon cancer cells in vitro, but only HOXB13 abolished tumor growth in nude mice.
|
20454457 |
2010 |
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We speculated that the DNA sequence variants (DSVs) within TBX18 gene promoter may mediate CHD development by affecting TBX18 levels and the cardiac gene regulatory network.
|
23749171 |
2013 |